Clinical Profile and Outcome of Pancreatic Head Malignancies Among Patients at a Tertiary Referral Hospital – A Seven-year Retrospective Review
Main Article Content
Abstract
Background: Malignancies of the head of the pancreas pose a significant global challenge due to their late presentation and the disease's aggressive nature. Modifiable risk factors, such as obesity, cigarette smoking, and alcohol consumption, are expected to increase, leading to a higher incidence of pancreatic cancer. Although the incidence of pancreatic cancer in Africa is expected to increase, data on pancreatic head malignancies in the region are abysmal. This study aimed to assess the current status of pancreatic cancer diagnosis and treatment options in Northern Tanzania.
Methods: We conducted a retrospective hospital-based study from January 2016 to December 2023 at a tertiary hospital in northern Tanzania. We aimed to investigate clinical presentation, management outcomes, and survival analysis. We retrieved data on patients diagnosed with pancreatic head tumours from the cancer registry. Data on demographics, clinical features, diagnostics, treatment, and outcomes were extracted from the cancer registry and hospital records. Descriptive statistics are presented as means with standard deviations (SD) or medians with interquartile ranges (IQR) for continuous variables, and frequencies with percentages for categorical variables. The chi-square (χ²) test assessed the association between categorical variables, while the grouped sample t-test or one-way ANOVA evaluated continuous outcomes at a 95% confidence interval. Significance was set at P < 0.05. Survival was analysed using the Kaplan–Meier method and log-rank tests, with Cox regression used to identify independent predictors of mortality. Ethical approval was obtained from the institutional review board, with consent waived due to the study’s retrospective nature.
Results: A total of 132 patients were included in this study, with a mean age of 61 years and a slight male predominance of 56.1%. Despite the low rate of chemotherapy administration (15.9%), treatment was associated with improved 30-day overall survival (OS 77.7% for recipients vs. 60.4% for non-recipients). Chronic pancreatitis was significantly associated with increased mortality (HR 5.92, p=0.019).
Conclusion: Our study reveals a high rate of late-stage presentations, limited diagnostic and treatment options, and markedly poor survival outcomes for patients with tumours of the head of the pancreas in northern Tanzania. The findings underscore the necessity for enhanced diagnostic and treatment strategies for pancreaticobiliary malignancies, given the significant mortality risks linked to certain factors and the limited use of invasive treatments. Further research is essential to develop more cost-effective interventions and enhance patient outcomes.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol (Madr). 2016;55(9-10):1158-1160. doi:10.1080/0284186X.2016.1197419
3. Hu JX, Lin YY, Zhao CF, et al. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J Gastroenterol. 2021;27(27):4298. doi:10.3748/WJG.V27.I27.4298
4. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019;10(1):10-27. doi:10.14740/wjon1166
5. Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18 (7):493-502. doi:10.1038/s41575-021-00457-x
6. Gaddam S, Abboud Y, Oh J, et al. Incidence of Pancreatic Cancer by Age and Sex in the US, 2000-2018. JAMA - Journal of the American Medical Association. American Medical Association. 2021; 326(20):2075-2077. doi:10.1001/jama.2021.18859
7. Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer. 2018;18(1). doi:10.1186/S12885-018-4610-4
8. Moraa F, Degu A. Survival Outcomes Among Pancreatic Cancer Patients at Kenyatta National Hospital. J Gastrointest Cancer. 2022;53(4):958-964. doi:10.1007/S12029-021-00723-W
9. Ilic I, Ilic M. International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: A joinpoint regression analysis. World J Gastroenterol. 2022;28(32):4698-4715. doi:10.3748/WJG.V28.I32.4698
10. Huang L, Jansen L, Balavarca Y, et al. Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: A large, international population-based study. BMC Med. 2018;16(1):1-15. doi:10.1186/S12 916-018-1120-9/TABLES/4
11. Lillemoe KD, Rikkers LF. Pancreaticoduodenectomy: The golden era. Ann Surg. 2006;244(1):16-17. doi:10.1097/01.sla.00002 26042.37420.f9
12. Cameron JL, He J. Two thousand consecutive pancreaticoduodenectomies. J Am Coll Surg. 2015; 220(4):530-536. doi:10.1016/j.jamcollsurg.2014.12.031
13. Dinagde TA, Abubeker Z. Surgical management of pancreatic cancer in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: a 5 years retrospective descriptive study. BMC Surg. 2024;24(1). doi:10.118 6/S12893-024-02503-2
14. Amri F, Koulali H, Jabi R, et al. Pancreatic cancer: experience from an emerging country in North Africa. J Cancer Res Clin Oncol. 2023;149 (15):14297. doi:10.1007/S00432-023-05245-5
15. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi:10.3322/CAAC.21763
16. Mutombo FL, Tsandiraki JK, Mchihiyo T, et al. Palliative biliodigestive bypass for unresectable pancreatic malignancy at Kilimanjaro Christian medical centre: a retrospective cross-sectional study. BMC Gastroenterol. 2025;25(1):103. doi:10.1186/s1 2876-025-03683-8
17. Cipolletta L, Rotondano G, Marmo R, Bianco MA, Italian Evidence-Based Gastroenterology & Hepatology Club. Endoscopic palliation of malignant obstructive jaundice: an evidence-based review. Dig Liver Dis. 2007;39(4):375-388. doi:10.1016/j.dl d.2006.12.016
18. Iruarrizaga E, Azkona E, Martinez M, et al. Percutaneous transhepatic biliary drainage (PTBD) and endoscopic retrograde cholangiopancreatography (ERCP) for malignant obstructive jaundice (OJ) in advanced digestive cancers. Journal of Clinical Oncology. 2011;29(4_suppl):348-348. doi:10.1200/jc o.2011.29.4_suppl.348
19. Chang KJ, Wiersema MJ. Endoscopic ultrasound-guided fine-needle aspiration biopsy and interventional endoscopic ultrasonography. Emerging technologies. Gastrointest Endosc Clin N Am. 1997;7(2):221-235. Accessed September 23, 2025. http://www.ncbi.nlm.nih.gov/pubmed/9101263
20. Inamdar S, Slattery E, Bhalla R, Sejpal D V., Trindade AJ. Comparison of Adverse Events for Endoscopic vs Percutaneous Biliary Drainage in the Treatment of Malignant Biliary Tract Obstruction in an Inpatient National Cohort. JAMA Oncol. 2016; 2(1):112-117. doi:10.1001/JAMAONCOL.2015.3670
21. Fakas S, Elias M, Lim D, Meytes V. Comparison of gastrojejunostomy techniques and anastomotic complications: a systematic literature review. Surg Endosc. 2021;35(12):6489-6496. doi:10.1007/S00464-020-08142-X
22. Loehrer AP, Chang DC, Hutter MM, et al. Health Insurance Expansion and Treatment of Pancreatic Cancer: Does Increased Access Lead to Improved Care? J Am Coll Surg. 2015;221(6):1015-1022. doi:10.1016/j.jamcollsurg.2015.09.010
23. Erlangga D, Suhrcke M, Ali S, Bloor K. The impact of public health insurance on health care utilisation, financial protection and health status in low- and middle-income countries: A systematic review. Buttigieg SC, ed. PLoS One. 2019;14(8) :e0219731. doi:10.1371/journal.pone.0219731
24. Kirkegård J, Mortensen FV, Cronin-Fenton D. Chronic Pancreatitis and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis. American Journal of Gastroenterology.Nature Publishing Group. 2017;112(9):1366-1372. doi:10.1038/ajg.2017.218
25. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993;328(20):1433-1437. doi:10.1056/NEJM1 99305203282001
26. Duell EJ, Lucenteforte E, Olson SH, et al. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Annals of Oncology. 2012;23(11):2964. doi:10.1093/ANNONC/MDS140
27. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913-2921. doi:10.1158/0008-5472.CAN-14-0155
28. Park W, Chawla A, O’Reilly EM. Pancreatic Cancer: A Review. JAMA. 2021;326(9):851-862. doi:10.1001/JAMA.2021.13027
29. Ghosn M, Ibrahim T, Assi T, El Rassy E, Kourie HR, Kattan J. Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. World J Gastroenterol. 2016;22(46):10124. doi:10.3748/W JG.V22.I46.10124
30. Hajatdoost L, Sedaghat K, Walker EJ, Thomas J, Kosari S. Chemotherapy in pancreatic cancer: A systematic review. Medicina (Lithuania).MDPI AG. 2018;54(3). doi:10.3390/medicina54030048
31. Funamizu N, Sakamoto A, Utsunomiya T, et al. Geriatric nutritional risk index as a potential prognostic marker for patients with resectable pancreatic cancer: a single-center, retrospective cohort study. Sci Rep. 2022;12(1):13644. doi:10.1038/s41598-022-18077-z
32. Furuse J, Osugi F, Machii K, Niibe K, Endo T. Effect of cancer cachexia on first-line chemotherapy in patients with advanced pancreatic cancer: a claims database study in Japan. Int J Clin Oncol. 2024; 29(4):456-463. doi:10.1007/S10147-024-02467-6
33. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073-1081. doi:10.1001/JAMA.201 0.1275